Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer
Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage
and follow-up stage. The enrolled patients will receive perioperative SOX chemotherapy, PD-1
antibody (sintilimab) and radical surgery, with or without preoperative CRT. The patients
were randomized by stratified permutated block randomization on a web-based system . The
status of peritoneal cytological examination (CY0 vs. CY1) was the stratification factor. The
study protocol was approved by the Ethics Committee of FUSCC. All patients provided written
informed consent before recruitment. Monitoring will be carried out in this tri